Ossianix
Biotechnology, 3675 Market St, Stevenage, Pennsylvania, 19104, United States, 11-50 Employees
Phone Number: 44**********
Who is OSSIANIX
OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biologic...
Read More
-
Headquarters: 3675 Market St, Stevenage, Pennsylvania, 19104, United States
-
Date Founded: 2012
-
Employees: 11-50
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 238990 |
Show More
Ossianix Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Ossianix
Answer: Ossianix's headquarters are located at 3675 Market St, Stevenage, Pennsylvania, 19104, United States
Answer: Ossianix's phone number is 44**********
Answer: Ossianix's official website is https://ossianix.com
Answer: Ossianix's revenue is Under $1 Million
Answer: Ossianix's SIC: 8731
Answer: Ossianix's NAICS: 238990
Answer: Ossianix has 11-50 employees
Answer: Ossianix is in Biotechnology
Answer: Ossianix contact info: Phone number: 44********** Website: https://ossianix.com
Answer: OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds. The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on neurodegereration, neurooncology, ALS, pain and botulism.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month